EffRx Pharmaceuticals SA is a commercial-stage pharmaceutical company, based in Switzerland, that develops and commercializes prescription medications for specialty indications. The primary focus is on therapeutics for men and women with musculoskeletal and genitourinary disorders. The business model is centered around providing superior clinical and commercial value propositions for physicians, payers and patients. We address real, unmet medical needs and strive to improve patient outcomes.
Location: Switzerland, Schwyz, Wilen
Employees: 11-50
Phone: +41 44 503 78 60
Total raised: $10.279183M
Founded date: 1998
Investors 1
| Date | Name | Website |
| - | Midroc New... | midroc.se |
Funding Rounds 2
| Date | Series | Amount | Investors | Deal News |
| 13.01.2015 | - | $2.3M | - | finsmes.co... |
| 01.10.2013 | Grant | $7.979183M | - | - |
Mentions in press and media 9
| Date | Title | Description | Source |
| 08.09.2023 | World Orphan Drug Alliance Welcomes Specialised Therapeutics | SEA's largest independent specialty pharma company Specialised Therapeutics (ST) has joined global p... | en.prnasia... |
| 30.05.2023 | EffRx Pharmaceuticals SA exits to Italy’s Abiogen Pharma | Established in 2010 in Freienbach (Switzerland) with around 15 employees, EffRx Pharmaceuticals SA... | startuptic... |
| 29.05.2023 | Abiogen Pharma Acquires 97,09% Stake in EffRx Pharmaceutical... | Abiogen Pharma, a Pisa, Italy-based company focused on osteoarticular and bone metabolism diseases, ... | finsmes.co... |
| 16.11.2021 | Diurnal : Alkindi® approved by Swissmedic for use in Switzer... | Market launch by EffRx Pharmaceuticals expected during H1 2022 to address unmet need in paediatric A... | marketscre... |
| 16.11.2021 | IP : Diurnal Group plc - Alkindi® approved by Swissmedic for... | Market launch by EffRx Pharmaceuticals expected during H1 2022 to address unmet need in paediatric A... | marketscre... |
| 17.04.2015 | Nine hot start-ups, 400 visitors and Joe Jimenez | Biotech is evolving into a mature industry – this is one of the results of the new Swiss Biotech R... | startuptic... |
| 26.01.2015 | EffRx – The next Swiss IPO candidate | Christer Rosén, Chairman & CEO stated, “This is a strong supportive round of financing to assi... | startuptic... |
| 13.01.2015 | EffRx Pharmaceuticals Raises over CHF2.3M in Equity Funding | EffRx Pharmaceuticals SA, a Freienbach, Switzerland-based specialty pharmaceutical company, raised o... | finsmes.co... |
| 27.09.2007 | Life sciences briefing: Thursday, Sept. 27, 2007 | Featured companies: AstraZeneca, Atlantis Components, Cara Therapeutics, CardioMems, Corium Internat... | venturebea... |